Skip Nav Destination
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Issue Archive
Table of Contents
BLOOD FLASHBACK
INSIDE BLOOD COMMENTARIES
PLENARY PAPER
REVIEW ARTICLE
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
Clinical Trials & Observations
Niels W. C. J. van de Donk,Philippe Moreau,Torben Plesner,Antonio Palumbo,Francesca Gay,Jacob P. Laubach,Fabio Malavasi,Hervé Avet-Loiseau,Maria-Victoria Mateos,Pieter Sonneveld,Henk M. Lokhorst,Paul G. Richardson
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Clinical Trials & Observations
Michael W. Deininger,J. Graeme Hodgson,Neil P. Shah,Jorge E. Cortes,Dong-Wook Kim,Franck E. Nicolini,Moshe Talpaz,Michele Baccarani,Martin C. Müller,Jin Li,Wendy T. Parker,Stephanie Lustgarten,Tim Clackson,Frank G. Haluska,Francois Guilhot,Hagop M. Kantarjian,Simona Soverini,Andreas Hochhaus,Timothy P. Hughes,Victor M. Rivera,Susan Branford
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Clinical Trials & Observations
Paul G. Richardson,Vânia T. M. Hungria,Sung-Soo Yoon,Meral Beksac,Meletios Athanasios Dimopoulos,Ashraf Elghandour,Wieslaw W. Jedrzejczak,Andreas Guenther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Robert L. Schlossman,Jian Hou,Philippe Moreau,Sagar Lonial,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Bourras-Rezki Bengoudifa,Claudia Corrado,Florence Binlich,Jesús F. San-Miguel
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas
Maciej Szydlowski,Przemyslaw Kiliszek,Tomasz Sewastianik,Ewa Jablonska,Emilia Bialopiotrowicz,Patryk Gorniak,Anna Polak,Sergiusz Markowicz,Eliza Nowak,Monika A. Grygorowicz,Monika Prochorec-Sobieszek,Anna Szumera-Cieckiewicz,Agata Malenda,Ewa Lech-Maranda,Krzysztof Warzocha,Przemyslaw Juszczynski
MYELOID NEOPLASIA
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
Virginie Chesnais,Aline Renneville,Andrea Toma,Jérôme Lambert,Marie Passet,Florent Dumont,Sylvie Chevret,Julie Lejeune,Anna Raimbault,Aspasia Stamatoullas,Christian Rose,Odile Beyne-Rauzy,Jacques Delaunay,Eric Solary,Pierre Fenaux,François Dreyfus,Claude Preudhomme,Olivier Kosmider,Michaela Fontenay,on behalf of the Groupe Francophone des Myélodysplasies
KIT D816V–mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression
Andres C. Garcia-Montero,Maria Jara-Acevedo,Ivan Alvarez-Twose,Cristina Teodosio,Laura Sanchez-Muñoz,Carmen Muñiz,Javier I. Muñoz-Gonzalez,Andrea Mayado,Almudena Matito,Carolina Caldas,Jose M. Morgado,Luis Escribano,Alberto Orfao
THROMBOSIS AND HEMOSTASIS
BLOOD WORK
-
Cover Image
Cover Image
![issue cover]()
CD115+-derived macrophages from wild-type C57BL/6 mice were incubated with human coagulation factor X (FX). Cells were then immunostained for human FX (green), while nuclei and polymerized actin were counterstained using 4′,6-diamidino-2-phenylindole (blue) and Alexa 647–labeled phalloidin (magenta), respectively. Images were acquired using widefield microscopy, original magnification ×63. See the article by Muczynski et al on page 778.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement
